London, UK – 31 October 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced that management will be participating in the following upcoming investor conferences during the month of November: BIO-Europe at Messe […]